Manufacturing of High-Concentration Monoclonal Antibody Formulations via Spray Drying—the Road to Manufacturing Scale

References

1. 1.↵
   1. Bowen M.,
   2. Turok B.,
   3. Maa Y.-F.

   Spray drying of monoclonal antibodies: investigating powder-based biologic drug substance bulk storage. Drying Technol. 2013, 31 (13–14), 1441–1450.

   OpenUrl
2. 2.↵
   1. Broadhead J.,
   2. Rouan S. K.,
   3. Hau I.,
   4. Rhodes C. T.

   The effect of process and formulation variables on the properties of spray-dried beta-galactosidase. J. Pharm. Pharmacol. 1994, 46 (6), 458–467.

   OpenUrlPubMed
3. 3.↵
   1. Maury M.,
   2. Murphy K.,
   3. Kumar S.,
   4. Mauerer A.,
   5. Lee G.

   Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G. Eur. J. Pharm. Biopharm. 2005, 59 (2), 251–261.

   OpenUrlPubMed
4. 4.↵
   1. Maa Y.-F.,
   2. Costantino H. R.,
   3. Nguyen P. A.,
   4. Hsu C. C.

   The effect of operating and formulation variables on the morphology of spray-dried protein particles. Pharm. Dev. Technol. 1997, 2 (3), 213–223.

   OpenUrlPubMed
5. 5.↵
   1. Andya J. D.,
   2. Maa Y.-F.,
   3. Costantino H. R.,
   4. Nguyen P.-A.,
   5. Dasovich N.,
   6. Sweeney T. D.,
   7. Hsu C. C.,
   8. Shire S. J.

   The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody. Pharm. Res. 1999, 16 (3), 350–358.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Costantino H. R.,
   2. Andya J. D.,
   3. Nguyen P.-A.,
   4. Dasovich N.,
   5. Sweeney T. D.,
   6. Shire S. J.,
   7. Hsu C. C.,
   8. Maa Y.-F.

   The effect of mannitol crystallization on the stability and aerosol performance of a spray-dried pharmaceutical protein, recombinant humanized anti-IgE monoclonal antibody. J. Pharm. Sci. 1998, 87 (11), 1406–1411.

   OpenUrlCrossRefPubMedWeb of Science
7. 7.↵
   1. Schule S.,
   2. Schultz-Fademrecht T.,
   3. Garidel P.,
   4. Bechtold-Peters K.,
   5. Frieb W.

   Stabilization of IgG1 in spray-dried powders for inhalation. Eur. J. Pharm. Biopharm. 2008, 69 (3), 793–807.

   OpenUrlPubMed
8. 8.↵
   1. Maury M.,
   2. Murphy K.,
   3. Kumar S.,
   4. Shi L.,
   5. Lee G.

   Effects of process variables on the powder yield of spray-dried trehalose on a laboratory spray dryer. Eur. J. Pharm. Biopharm. 2005, 59 (3), 565–573.

   OpenUrlCrossRefPubMedWeb of Science
9. 9.↵
   1. Andya J. D.,
   2. Hsu C. C.,
   3. Shire S. J.

   Mechanisms of aggregate formation and carbohydrate excipient stabilization of lyophilized humanized monoclonal antibody formulations. AAPS PharmSci 2003, 5 (2), 21–31.

   OpenUrl
10. 10.↵
    1. Jovanovic N.,
    2. Bouchard. A.,
    3. Hofland G. W.,
    4. Witkamp G. J.,
    5. Crommelin D. J.,
    6. Jiskoot W.

    Distinct effects of sucrose and trehalose on protein stability during supercritical fluid drying and freeze-drying. Eur. J. Pharm. Sci. 2006, 27 (4), 336–345.

    OpenUrlPubMed
11. 11.↵
    1. Jain N. K.,
    2. Roy I.

    Effect of trehalose on protein structure. Protein Sci. 2009, 18 (1), 24–36.

    OpenUrlCrossRefPubMedWeb of Science
12. 12.↵
    1. Chang L.,
    2. Shepherd D.,
    3. Sun J.,
    4. Ouellette D.,
    5. Grant K. L.,
    6. Pikal M. J.

    Mechanism of protein stabilization by sugars during freeze-drying and storage: native structure preservation, specific interaction, and/or immobilization in a glassy matrix? J. Pharm. Sci. 2005, 94 (7), 1427–1444.

    OpenUrlPubMed
13. 13.↵
    1. Wang. Y.,
    2. Fei D.,
    3. Vanderlaan M.,
    4. Song A.

    Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7 (4), 335–345.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Park J. W.,
    2. Hongi T. K.,
    3. Carter P.,
    4. Asgarit H.,
    5. Guot L. Y.,
    6. Keller G. A.,
    7. Wirthii C.,
    8. Shalabyii R.,
    9. Kotrsi C.,
    10. Woodt W. I.,
    11. Papahadjopoulost D.,
    12. Benz C. C.

    Development of anti-p185IER2 immunoliposomes for cancer therapy. Proc. Natl. Acad. Sci. USA 1995, 92 (5), 1327–1331.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Gottschalk U.

    1. Li Y.,
    2. Kahn D. W.,
    3. Galperina O.,
    4. Blatter E.,
    5. Luo R.,
    6. Wu Y.,
    7. Zhang G.

    Development of a Platform Process for the Purification of Therapeutic Monoclonal Antibodies. In Process Scale Purification of Antibodies; Gottschalk U., Ed.; John Wiley & Sons: New York, 2011.
16. 16.↵
    1. Shire S. J.,
    2. Shahrokh Z.,
    3. Liu J.

    Challenges in the development of high protein concentration formulations. J. Pharm. Sci. 2004, 93 (6), 1390–1402.

    OpenUrlCrossRefPubMedWeb of Science
17. 17.↵
    1. Liu J.,
    2. Shire S. J.

    Reduced-viscosity concentrated protein formulations. U.S. Patent 8,142,776 B2, 2012.
18. 18.↵
    1. Liu J.,
    2. Shire S. J.

    High concentration antibody and protein formulations. U.S. Patent Application Publication US 2004/0197324 A1, 2004.
19. 19.↵
    1. Jezek J.,
    2. Darron N. J.,
    3. Derham B. K.,
    4. Royle N.,
    5. Simpson I.

    Biopharmaceutical formulations for pre-filled delivery devices. Expert Opin. Drug Deliv. 2013, 10 (6), 811–828.

    OpenUrlPubMed
20. 20.↵
    1. Bowen M.,
    2. Armstrong N.,
    3. Maa Y.-F.

    Investigating high-concentration monoclonal antibody powder suspension in nonaqueous suspension vehicles for subcutaneous injection. J. Pharm. Sci. 2012, 101 (12), 4433–4443.

    OpenUrlPubMed
21. 21.↵
    1. Overcashier D. E.,
    2. Chan E. K.,
    3. Hsu C. C.

    Technical considerations in the development of prefilled syringes for protein products. Am. Pharm. Rev. 2006, 9 (7), 77–83.

    OpenUrl
22. 22.↵
    1. Sukumar M.,
    2. Doyle B. L.,
    3. Combs J. L.,
    4. Pekar A. H.

    Opalescent appearance of an IgG1 antibody at high concentrations and its relationship to noncovalent association. Pharm. Res. 2004, 21 (7), 1087–1093.

    OpenUrlPubMed
23. 23.↵
    1. He F.,
    2. Woods C. E.,
    3. Trilisky E.,
    4. Bower K. M.,
    5. Litowski J. R.,
    6. Kerwin B. A.,
    7. Becker G. W.,
    8. Narhi L. O.,
    9. Razinkov V. I.

    Screening of monoclonal antibody formulation based on high-throughput thermostability and viscosity measurements: design of experiment and statistical analysis. J. Pharm. Sci. 2011, 100 (4), 1330–1340.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Nony P.,
    2. Girard P.,
    3. Chabaud S.,
    4. Hessel L.,
    5. Thebault C.,
    6. Boissel J. P.

    Impact of osmolality on burning and sensation during and immediately after intramuscular injection of 0.5 ml of vaccine suspensions in healthy adults. Vaccine 2001, 19 (27), 3645–3651.

    OpenUrlPubMed
25. 25.↵
    1. Zietkiewiz W.,
    2. Kostrewska E.,
    3. Gregor A.

    In vivo studies on the action on the tissue of the osmolality of parenterally administered drugs. Grzyby Drozdzopodobne 1977, 23, 869–870; The Ralph McElroy Translation Company: Austin, TX.

    OpenUrl
26. 26.↵
    1. Keele C. A.,
    2. Armsotrong D.

    Production of Pain by Hypertonic and Hypotonic Solutions. In Substance Producing Pain and Itch; Edward Arnold (Publishers), Ltd.: London, 1964; pp 67–72.
27. 27.↵
    1. Enliang L.,
    2. Yingmin W.

    A new collection theory of cyclone separators. AIChE J. 1989, 35 (4), 666–669.

    OpenUrlCrossRefWeb of Science